Seaport Therapeutics - 七日Glyphago给药实现治疗性阿戈美拉汀暴露，无肝酶升高

美股速递06-08

Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。

研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1159152611?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-08 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159152611","market":"us","top_or_hot":-1,"title":"Seaport Therapeutics - 七日Glyphago给药实现治疗性阿戈美拉汀暴露，无肝酶升高","media":"美股速递","content":"<p>Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。</p>\n<p>研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seaport Therapeutics - 七日Glyphago给药实现治疗性阿戈美拉汀暴露，无肝酶升高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeaport Therapeutics - 七日Glyphago给药实现治疗性阿戈美拉汀暴露，无肝酶升高\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-08 19:04 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。\n研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPTX","symbol_name":"Seaport Therapeutics","start_time":0,"source_url":"","article_id":"1159152611","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159152611","pubTimestamp":1780916669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。\n研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SPTX":"Seaport Therapeutics","BK4007":"制药"},"translate_title":"Seaport Therapeutics-Seven-day Glyphago dosing achieves therapeutic agomelatine exposure without elevated liver enzymes","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPTX":1},"content_text":"Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。\n研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159152611","isCrawlerRequest":true}